Eckert & Ziegler Strahlen und Medizintechnik AG
XETRA:EUZ
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
33.2
49.66
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one EUZ stock under the Base Case scenario is 57.08 EUR. Compared to the current market price of 42.9 EUR, Eckert & Ziegler Strahlen und Medizintechnik AG is Undervalued by 25%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Eckert & Ziegler Strahlen und Medizintechnik AG
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for EUZ cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Eckert & Ziegler Strahlen und Medizintechnik AG
Balance Sheet Decomposition
Eckert & Ziegler Strahlen und Medizintechnik AG
Current Assets | 277.2m |
Cash & Short-Term Investments | 97.6m |
Receivables | 63.2m |
Other Current Assets | 116.5m |
Non-Current Assets | 203.7m |
Long-Term Investments | 20.9m |
PP&E | 115.9m |
Intangibles | 52.5m |
Other Non-Current Assets | 14.4m |
Current Liabilities | 99.9m |
Accounts Payable | 6m |
Other Current Liabilities | 93.9m |
Non-Current Liabilities | 132.6m |
Long-Term Debt | 42.7m |
Other Non-Current Liabilities | 89.9m |
Earnings Waterfall
Eckert & Ziegler Strahlen und Medizintechnik AG
Revenue
|
423.1m
EUR
|
Cost of Revenue
|
-216.7m
EUR
|
Gross Profit
|
206.4m
EUR
|
Operating Expenses
|
-114.8m
EUR
|
Operating Income
|
91.6m
EUR
|
Other Expenses
|
-44.2m
EUR
|
Net Income
|
47.4m
EUR
|
Free Cash Flow Analysis
Eckert & Ziegler Strahlen und Medizintechnik AG
EUR | |
Free Cash Flow | EUR |
EUZ Profitability Score
Profitability Due Diligence
Eckert & Ziegler Strahlen und Medizintechnik AG's profitability score is 63/100. The higher the profitability score, the more profitable the company is.
Score
Eckert & Ziegler Strahlen und Medizintechnik AG's profitability score is 63/100. The higher the profitability score, the more profitable the company is.
EUZ Solvency Score
Solvency Due Diligence
Eckert & Ziegler Strahlen und Medizintechnik AG's solvency score is 85/100. The higher the solvency score, the more solvent the company is.
Score
Eckert & Ziegler Strahlen und Medizintechnik AG's solvency score is 85/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EUZ Price Targets Summary
Eckert & Ziegler Strahlen und Medizintechnik AG
According to Wall Street analysts, the average 1-year price target for EUZ is 57.27 EUR with a low forecast of 55.55 EUR and a high forecast of 60.17 EUR.
Dividends
Current shareholder yield for EUZ is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
EUZ Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Eckert & Ziegler Strahlen- und Medizintechnik AG engages in the provision of isotope technology for medical, scientific, and industrial use. The company is headquartered in Berlin, Berlin and currently employs 866 full-time employees. The company went IPO on 2008-02-25. The firm operates through three segments: Radiation Therapy, Isotope Products and Radiopharma. The Radiation Therapy segment operates through Eckert & Ziegler BEBIG and produces and distributes medical products for the treatment of cancer using brachytherapy. The Isotope Products segment provides sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration and environmental monitoring sources and solutions, as well as bulk radioisotopes for pharmaceutical, therapeutic and industrial product manufacturers. The Radiopharma segment specializes in molecular imaging and nuclear medicine, and supplies various radiopharmaceuticals, radiochemicals and related equipment.
Contact
IPO
Employees
Officers
The intrinsic value of one EUZ stock under the Base Case scenario is 57.08 EUR.
Compared to the current market price of 42.9 EUR, Eckert & Ziegler Strahlen und Medizintechnik AG is Undervalued by 25%.